Evidence map›Paper›PMID 41565641›Full record

ArticleNature communications2026

Serine inhibits granulosa cell ferroptosis to maintain ovarian function.

Hao-Cheng Gu, You-Qiong Zhuo, Ling-Fang Wang, Yu-Wei Zhang, Dong-Shui Li, Ling-Qin Chen, Zhi-Hua Li, Yun-Yue Wang, Yi-Kai Wang, Hui-Ting Liao and 5 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hao-Cheng Gu *School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.
You-Qiong Zhuo *The National Engineering Research Center for Bioengineering Drugs and the Technologies, Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.
Ling-Fang Wang *The National Engineering Research Center for Bioengineering Drugs and the Technologies, Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.
Yu-Wei ZhangThe National Engineering Research Center for Bioengineering Drugs and the Technologies, Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.
Dong-Shui LiDepartment of Assisted Reproduction, The First Affiliated Hospital of Nanchang University, Nanchang, P. R. China.
Ling-Qin ChenDepartment of Assisted Reproduction, The First Affiliated Hospital of Nanchang University, Nanchang, P. R. China.
Zhi-Hua LiDepartment of Breast Surgery, Third Hospital of Nanchang, Jiangxi Breast Specialist Hospital, Nanchang, P.R. China.
Yun-Yue WangDepartment of Breast Surgery, Third Hospital of Nanchang, Jiangxi Breast Specialist Hospital, Nanchang, P.R. China.
Yi-Kai WangSchool of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.
Hui-Ting LiaoThe National Engineering Research Center for Bioengineering Drugs and the Technologies, Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.
Jia-Qin WuThe National Engineering Research Center for Bioengineering Drugs and the Technologies, Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.
Shi-Qing TaoThe National Engineering Research Center for Bioengineering Drugs and the Technologies, Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.
Xing-Yu WeiThe National Engineering Research Center for Bioengineering Drugs and the Technologies, Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.
Ke-Yu DengSchool of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China. dky@ncu.edu.cn.
Hong-Bo XinSchool of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China. xinhb@ncu.edu.cn.ORCID http://orcid.org/0000-0002-4257-207X

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82270302National Natural Science Foundation of China (National Science Foundation of China) 82470454
6 · The paper itself

Abstract

Cyclophosphamide (CTX) is a primary medicine for curing breast cancer which often causes premature ovarian insufficiency (POI). Our recent publication reveals that CTX induces POI by promoting the expression of SLC1A4, a transporter of serine efflux, in ovarian granulosa cells (GCs). Here, we report that there is a closed connection between the reduction of serum serine and ovarian hypofunction in the breast cancer patients treated with CTX or women of childbearing age who are suffered from the staying-up-late. Additionally, we observe that dietary serine supplementation protects mice from CTX-induced POI without altering its anti-breast cancer. Furthermore, we demonstrate that the elevated serine promotes S1P synthesis, and in turn, inhibits the nuclear translocation of Nrf2 and consequent HO-1 expression, to suppress ferroptosis in GCs. Our study reveals that the chemotherapy-induced or idiopathic POI share the same mechanisms, indicating that serine is a critical factor for maintaining ovarian function.

Indexed as

FerroptosisGranulosa CellsOvaryPrimary Ovarian InsufficiencySerineAnimalsCyclophosphamideFemaleHeme Oxygenase-1HumansMiceNF-E2-Related Factor 2CyclophosphamideHeme Oxygenase-1NF-E2-Related Factor 2Serine

Identifiers

PMID41565641
PMCPMC12913872

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.